Search Results
Jun 22, 2026, 04:29 ET ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA
action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of
More news about: DJS Law Group LLP
Jun 21, 2026, 07:58 ET ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
failed to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; and (4) as a result, defendants' statements about ADMA Biologics' business, operations,
More news about: THE ROSEN LAW FIRM, P. A.
Jun 19, 2026, 22:00 ET ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
ADMA Biologics, Inc. ("ADMA" or the "Company") (NasdaqGM: ADMA) of a class action securities lawsuit.
More news about: Kahn Swick & Foti, LLC
Jun 19, 2026, 07:48 ET ADMA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
failing to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; and (4) as a result, defendants' statements about ADMA Biologics' business, operations,
More news about: Faruqi & Faruqi, LLP
Jun 18, 2026, 14:00 ET ADMA Biologics, Inc. (ADMA) Class Action Lawsuit: Investors Face August 10, 2026, Deadline
Did you buy ADMA securities between August 9, 2024 and March 25, 2026?Affected ADMA Investor SummaryWho: ADMA Biologics, Inc. (
More news about: Kessler Topaz Meltzer & Check, LLP
Jun 18, 2026, 10:07 ET ADMA Shareholder Alert: ADMA BIOLOGICS, INC. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
millions recovered for investors.Frequently Asked Questions About the ADMA LawsuitQ: What specific misstatements does the ADMA lawsuit allege? A: The complaint alleges ADMA made materially false or misleading statements regarding revenue recognition
More news about: SueWallSt.com
Jun 18, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA
June 18, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at
More news about: Pomerantz LLP
Jun 17, 2026, 10:13 ET ADMA DEADLINE: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline
hundreds of millions of dollars for investors.Frequently Asked Questions About the ADMA LawsuitQ: Who is eligible to join the ADMA investor lawsuit? A: Investors who purchased ADMA stock or securities between August 9, 2024 and March 25, 2026 and suffered financial losses may
More news about: Levi & Korsinsky, LLP
Jun 17, 2026, 08:15 ET ADMA INVESTOR DEADLINE: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
lawsuit. Captioned Mazzarino v. ADMA Biologics, Inc., No. 26-cv-06918 (D.N.J.), the ADMA Biologics class action lawsuit charges ADMA Biologics as well as certain of ADMA Biologics' top executive officers with violations of the Securities Exchange Act of 1934.
More news about: Robbins Geller Rudman & Dowd LLP
Jun 16, 2026, 18:14 ET ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
failed to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; and (4) as a result, defendants' statements about ADMA Biologics' business, operations,
More news about: THE ROSEN LAW FIRM, P. A.
Jun 16, 2026, 09:15 ET ADMA UPCOMING DEADLINE : The Gross Law Firm Alerts ADMA Biologics, Inc. Stockholders of Securities Class Action - Contact the Firm
failed to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; (4) as a result, defendants' statements about ADMA Biologics' business, operations,
More news about: The Gross Law Firm
Jun 16, 2026, 06:07 ET ADMA Court Deadline: ADMA Biologics Investors are Notified of the Important August 10 Deadline in the Pending Securities Fraud Class Action Lawsuit
investors in ADMA securities. The class action is pending in the U.S. District Court for the District of New Jersey. It is captioned Mazzarino v. ADMA Biologics, Inc., et al., No. 26-cv-6918.Why is ADMA Biologics Being Sued for Securities Fraud? ADMA has been sued
More news about: Bleichmar Fonti & Auld LLP
Jun 15, 2026, 12:00 ET Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
bgandg.com/ADMA.ADMA Case DetailsThe Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that:ADMA Biologics engaged in an undisclosed
More news about: Bronstein, Gewirtz & Grossman, LLC
Jun 12, 2026, 22:00 ET ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA
ADMA Biologics, Inc. (NasdaqGM: ADMA) ("ADMA" or the "Company"), if they purchased or otherwise acquired the Company's securities between August 9, 2024 and March 25, 2026,
More news about: ClaimsFiler
Jun 12, 2026, 18:47 ET ADMA Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against ADMA Biologics, Inc.
stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9,2024 and March 25, 2026. ADMA Biologics, Inc., is a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived
More news about: Robbins LLP
Jun 11, 2026, 19:07 ET ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
failed to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; and (4) as a result, defendants' statements about ADMA Biologics' business, operations,
More news about: THE ROSEN LAW FIRM, P. A.
Jun 11, 2026, 15:15 ET ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead the ADMA Biologics Class Action Lawsuit
acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the "Class Period"), have until August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. Captioned Mazzarino v. ADMA Biologics,
More news about: Robbins Geller Rudman & Dowd LLP
Jun 04, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 28, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 23, 2026, 07:23 ET Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.So What: If you purchased ADMA Biologics securities you may be entitled to compensation
More news about: THE ROSEN LAW FIRM, P. A.
May 21, 2026, 15:33 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 18, 2026, 17:28 ET Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.So What: If you purchased ADMA Biologics securities you may be entitled to compensation
More news about: THE ROSEN LAW FIRM, P. A.
May 14, 2026, 20:15 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 12, 2026, 17:24 ET Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.So What: If you purchased ADMA Biologics securities you may be entitled to compensation
More news about: THE ROSEN LAW FIRM, P. A.
May 08, 2026, 03:18 ET Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.So What: If you purchased ADMA Biologics securities you may be entitled to compensation
More news about: THE ROSEN LAW FIRM, P. A.